Row over Lancet alert on Crestor
GPs have been urged by The Lancet to think twice before prescribing the statin Crestor (rosuvastatin). The accusation that manufacturer Astra-Zeneca 'forced' Crestor into the market despite there being 'no reliable data about efficacy and safety' has drawn a furious response from the company.
The Lancet said: 'Doctors should pause before prescribing this drug and tell patients the truth that, compared with its competitors, rosuvastatin has an inferior evidence base supporting its safe use.'
But AstraZeneca chief executive Sir Tom McKillop said Crestor had been subject to clinical trials in more than 10,000 patients and had been approved by over 30 regulatory bodies. He said the drug's profile with 80 per cent of patients on 10mg reaching LDL cholesterol goals and increasing their HDL cholesterol was 'unmatched'.